
Sign up to save your podcasts
Or


He offers what he believes are learnings from this morning's data, and describes the data Instil's partner ImmuneOnco has derived for their asset to date. Plus, plans for future data later this year and getting a U.S. study up and running.
By BiotechTV4.3
66 ratings
He offers what he believes are learnings from this morning's data, and describes the data Instil's partner ImmuneOnco has derived for their asset to date. Plus, plans for future data later this year and getting a U.S. study up and running.

3,223 Listeners

1,902 Listeners

123 Listeners

324 Listeners

61 Listeners

9,960 Listeners

86 Listeners

34 Listeners

353 Listeners

19 Listeners

60 Listeners

514 Listeners

41 Listeners

0 Listeners

4 Listeners

2 Listeners

6 Listeners

46 Listeners